Vutrisiran Snags FDA Approval for TTR Amyloidosis Cardiomyopathy

(MedPage Today) -- Gene-silencing therapy vutrisiran (Amvuttra) graduated to a broad indication in treatment of transthyretin amyloidosis cardiomyopathy, as Alnylam Pharmaceuticals announced expanded FDA approval.
Vutrisiran, a transthyretin-directed...